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Comparison of 10 hemostatic dressings in a groin
puncture model in swine
Françoise Arnaud, PhD,a,b Kohsuke Teranishi, MD,a Toshiki Tomori, MD,a Walter Carr, PhD,a and
Richard McCarron, PhD,a,b Silver Spring and Bethesda, Md
Background: The use of mineral (clay) or biologic (chitosan) materials has improved the efficacy of dressings used in the
bleeding control of noncompressible areas. A series of novel manufactured products already evaluated in a vascular
transection model was further compared in a severe vascular puncture injury model.
Methods: Ten hemostatic dressings were tested in anesthetized Yorkshire swine hemorrhaged for 45 seconds in a femoral
arterial puncture model. Application of these dressings was followed by 5 minutes of compression (about 175 mm Hg),
and at 15 minutes, 500 mL resuscitation fluid (Hextand) was infused during a 30-minute period. The animals were
monitored for a 3-hour experimental observation period. Primary outcomes were incidence of bleeding after dressing
application and animal survival.
Results: Blood loss was 18.8%  5.2% estimated blood volume (EBV) after 45 seconds of free bleeding. Relative
performance of dressings is characterized as groups of dressings that performed similarly. Recurrence of bleeding after
application was observed with most dressings and was lower with Woundstat, Celox, X-Sponge, and ACS (35% 49%)
compared with FP-21, Hemcon, Chitoflex, and Bloodstop (79%  43%; P < .01). Blood loss after treatment was 25.3% 
18.4% EBV for the top four dressings and 53.0%  18.4% EBV for the bottom four (P < .05). Survival was higher for
top four vs bottom four dressings (78% 12% vs 25% 0%, respectively; P< .01). Overall performance of these dressings
according to survival, incidence of bleeding, and post-treatment blood loss, yielded similar ranking as with a previously
tested transection injury model.
Conclusions:The findings indicated that the efficacy of Woundstat, Celox, X-Sponge, and ACSwere similar and superior
in improving survival, hemostasis, and maintenance of mean arterial pressure in an actively bleeding wound caused in this
severe vascular injury model. ( J Vasc Surg 2009;50:632-9.)
Clinical Relevance: Major improvements have been made in the development of novel dressings with hemostatic
properties to control heavy bleeding in noncompressible areas. Hemostatic dressings offer promise in the military and
civilian surgical environment for hemorrhage control in difficult situations. This animal-based study identified dressings
with good absorption and good clotting abilities that ranked superior in terms of control of rebleeding. Also, these
dressings might be beneficial in well-attended or remote surgical theaters as well as for first aid bandaging in extreme
sport.Methods to suppress massive external hemorrhage
should be provided immediately after injury and should
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632control active bleeding within minutes to prevent death or
consequences of hypovolemia and hypoperfusion.1-3 The
amount of blood lost relates to the type of injury and
dictates survival. Compression points remain a very effec-
tive method to stop bleeding in extremities.4-6 In most
noncompressible cases, standard of care treatment of a slow
hemorrhage involves using cellulose-based compressed
gauze (eg, Kerlix dressings) as the first action to absorb
blood.7 The use of these simple dressings assumes that
hemostasis will eventually be restored naturally by clot
formation, vessel constriction, or retraction, but subse-
quent bleeding (rebleeding) may occur and require addi-
tional dressing applications.
As an alternative to bleeding control, tourniquets, used
efficiently for extremities, are not suited for noncompress-
ible areas such as the neck, peritoneum, or groin. Promising
solutions for controlling rapid bleeding in these areas could
come from novel hemostatic dressings with maximum effi-
cacy in a single application.4,8 By adding an active hemo-
static agent to a supportive matrix, the first generation of
improved dressings has contributed to better bleeding con-
trol in noncompressible areas.9-16 The selection of dress-
ings for military conflict-related situations, including non-
nthes
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products that exhibit superior performance in these chal-
lenging injuries.
Recently, major developments have been made in the
composition, texture, and active constituent materials of
hemostatic dressings.11,17-20 The relative efficacy of these
dressings may be influenced by their form, nature, and
application, especially in trauma patients with bleeding
wounds. These improved hemostatic dressings were evalu-
ated in an animal vascular transection injury model and
showed better performance than standard compressed
gauze, but the difference between dressings was minimal.19
Owing to different modes of action and presentation of
these diverse products, it is reasonable to assume that
effectiveness will vary with the severity of injury. For exam-
ple, some hemostatic dressings may perform better in high-
pressure bleeding injuries, whereas others may be more
effective in slower bleeding injuries. Therefore, efficacy of
these dressings needs to be confirmed for bleeding control
and long-term secure placement on the wound (when the
casualty is moved through difficult terrains and situations
or experiences a long delay for evacuation) in other types of
severe injury models.
Even though in the transection model the rupture of
vessels and muscles is designed to represent multiple inju-
ries associated with combat injury,21 application of ban-
dages may not be sufficiently challenged by active bleeding
in this model. In a continuous effort to find the best
performing dressings, we evaluated products in a severe
vascular puncture injury model with a high initial bleeding
rate and low survival.20,22
The objective of this study is to compare the efficacy of
hemostatic dressings of different nature (eg, granular, fabric-
based) with standard gauze. The specific hypotheses of this
project are that the new products are more efficacious than
standard gauze in (1) arresting bleeding, (2) preventing
additional bleeding over time, and (3) improving survival.
Table I. Description of hemostatic products tested in wou
Test products Manufacturer
Powder/granular agents
ACS (ACS) Z-Medica Corp Wallingford, Con
Celox (CEL) Sam Medical Products Newport, O
Instaclot (IC) Emergency Medical Devices Loxa
WoundStat (WS) TraumaCure, Inc. Bethesda, Md
Solid (flexible) agents
Alpha Bandage (AB) H & H Bena, Va
BloodStop (BLS) LifeScience, Santa Clara, Calif
X-Sponge (XS) Z-Medica Corp Wallingford, Con
Solid (rigid) agents
Chitoflex (CHI) HemCon Medical Technologies,
Portland, OreHemCon (HC)
Polymem FP-21 (FP-21) Ferris Mfg. Corp. Burr Ridge, Ill
aThe abbreviations used in this article for each product are indicated in pareFurther, they should have comparable or better efficacythan Zeolite and ACS hemostatic dressings currently
approved for use in United States (U.S.) military.
MATERIALS AND METHODS
Hemostatic dressings. The products used for this
study and their abbreviations referred to throughout are
listed in Table I. The hemostatic products and the standard
compressed gauze bandage (SD; H&H compressed gauze,
H&H Associates, Bena, Va) were categorized according to
nature, form, and composition. Hemostatic dressings were
made of a wide range of material from mineral-based prod-
ucts made of zeolite, smectite, and kaolin to biologically
based products made of chitin. We tested 10 different
hemostatic agents and one control SD (11 groups in total).
A more detailed description of each of the products was
reported by Arnaud et al in 2009.19
Animal model. The study adhered to the principles in
the Guide for the Care and Use of Laboratory Animals,
(National Research Council, 1996 Edition). The study was
approved by the Naval Medical Research Center/Walter
Reed Army Institute of Research Institutional Animal Care
and Use Committee (IACUC). All procedures were per-
formed in accordance to the Animal Welfare Act and in an
animal facility approved by the Association for Assessment
and Accreditation for Laboratory Animal Care Interna-
tional (AAALAC).
Yorkshire swine, weighing 25 to 35 kg (Animal Biotech
Industry; Danboro, Pa), were refrained from food the night
before the experiment but had free access to water. Surgical
techniques and animal monitoring are described in a previ-
ous study by Arnaud et al.19 Briefly, anesthesia was induced
with intramuscular injection of ketamine HCl (30 mg/kg;
Henry Schein, Inc, Melville, NY) and inhalation of isoflu-
rane (3% to 4%). The animals were allowed to breathe
spontaneously or through mechanical ventilation when
necessary (Narkomed M ventilator, North American
Dräger Telford, PA). An 18- to 20-gauge angiocatheter
uncture model by form and typea
Description
Mineral Al/Si Zeolite with attenuated exothermic
reaction
Chitosan based granules
ee, Fla Proprietary composition powder
Polymer/mineral Al/Si granules
4”  4” interwoven fabric, bamboo and fiberglass
Coated deoxidized cellulose based gauze
4”  4” gauze coated with proprietary hemostatic
formulation
3”  28” roll made of chitosan
4”  4” pad made of chitosan
3-layer Dextran/chitosan based 4”  4” wafer
is.nd p
n
re
hatch
n
Inc.(Schein Care Corp, Irvine, Calif) was placed in the right
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Life Sciences, Irvine, Calif) in the right external jugular
vein, and vital signs were continuously monitored and
recorded. Pulse oximetry (Datex-Ohmeda; SurgiVet,
Waukesaha, NJ) was obtained from the tongue, tail, or ear.
Puncture model. The skin of the inguinal area of the
right thigh was incised longitudinal to the groin approxi-
mately 12 cm to expose the femoral vasculature. The fem-
oral artery was invasively isolated for approximately 4 cm on
the distal side of the groin, free of fascia tissue. Lidocaine
(Henry Schein, Inc) (1% to 2%) was spread on the artery to
maximize dilation of the vessel. Any proximal side branches
from the artery were ligated to avoid redirection of blood to
the main circulation. After a brief period of stabilization
and recording of baseline data, bulldog clamps were placed
on the artery and a 4-mm hole was perforated by an aortic
vascular punch (APU440,Medtronic,Minneapolis,Minn).
After this injury, the clamps were removed to produce
uncontrolled hemorrhage (time 0 [T0]) resulting in imme-
diate release of high-pressure arterial blood. Shed blood
was removed by suction directed towards the blood accu-
mulating in the groin cavity and not directly to the injured
vessel area. Blood was aspirated into a vacuum bowl that
was continuously weighed. The collected blood was re-
corded as pretreatment blood loss. Because of the high
shear stress bleeding and shed blood accumulation, blood
was still present in the wound cavity at the time of the
dressing application (T1).
Treatment and monitoring. The animals were ran-
domly assigned to one of the 11 bandage regimens (n  8
per group). Rectal temperature was monitored and main-
tained between 37°C and 39°C using a Bair Hugger device
(Model 505, Bair Hugger, Minn). After uncontrolled
bleeding for 45 seconds (T1), the treatment consisted of
placement of the test dressing on the injured site with a SD
placed over it. The test dressings were applied according to
the manufacturer’s directions for use.
A constant pressure of 175 28 mmHg (measured by
HM 28 pressure monitor, Dwyer, Calif) was manually
applied over the wound with the dressings for 5 minutes.
The pressure was then released and the skin apposed over
the dressing, which resulted in a residual pressure of 30 5
mm Hg. At 15 minutes (T15), resuscitation was initiated
by intravenous administration of 500 mL of isotonic col-
loid (Hextend, Biotime, Abbott, Abbott Park, Ill) through
the external jugular vein over 30 minutes until T45 using a
pump set (Masterflex, Cole Parmer, Vernon Hills, Ill). No
additional fluid was administered regardless of the mean
arterial pressure (MAP) or the blood loss.
The dressings remained in place on the wound, un-
touched for the remainder of the experiment. All animals
were monitored until the end of the third hour (T180), at
which time the dressings were removed, and the injured site
was inspected for presence of clots. Animals that survived
until T180were euthanized with Euthasol solution (0.3mL/
kg; Virbac AH, Inc, Fort Worth, Tex).
Recording and data acquisition. Shed blood vol-
ume was collected in a sealed container (2 L MediVac;CardinalHealth, Dublin, Ohio) and continuously weighed
on a top-loading scale (PS 5100, Mettler-Toledo Inc,
Columbus, Ohio). Rectal and wound temperature at the
interface of wound blood and dressing were continuously
recorded using temperature probes (BAT 12, Physitemp,
Clifton, NJ). Blood pressure (MAP) and heart rate were
continuously measured on a blood pressure analyzer (BPA;
Micro-Med Inc, Louisville, Ky). Data were organized in an
Excel spreadsheet (Microsoft Corp, Redmond, Wash) for
further analysis. Arterial and mixed venous samples were
taken at T0, T5, T15, T45, T60, T120, and T180. Blood
samples were analyzed for complete blood count (Pentra
60C, HoribaABX, Irvine, Calif), thromboelastography
(TEG; TEG5000, Haemoscope, Niles, Ill), coagulation
parameters (Sta Compact, Diagnostica Stago, Parsippany,
NJ), and blood gas using the ABL 750 analyzer (Radiom-
eter, Copenhagen, Denmark).
Blood loss was divided into pretreatment (initial injury
hemorrhage to 45 seconds) and post-treatment (from T1
to end point). Aspirated shed blood was continuously
recorded and total post-treatment blood loss was calculated
as measured shed blood, blood absorbed in test dressing,
and blood absorbed in the SD, each weighed at the end of
the experiment.
Recurrence of bleeding (rebleeding) was recorded to
assess each product for bleeding control after release of
the 5-minute manual compression or when MAP
reached 40 mmHg, or both. Recurrence of bleeding was
accounted by incidence of aspiration (ie, no bleeding or
bleeding retained in the dressing vs blood oozing from
the dressings and able to be aspirated). Given this re-
bleeding definition, dressing effectiveness was analyzed
in terms of percentage of animals that (1) exhibited one
occurrence of rebleeding between the application of
dressing and end of experiment, (2) exhibited more than
one occurrence of rebleeding, and (3) that died before
the second rebleeding event.
Statistical analysis. The design of the study was to
evaluate each dressing on eight animals, unless there was a
survival rate of50% after testing the first four animals in a
treatment group. In that case, group size was limited to
four animals. This criterion of 50% survival was also applied
after testing six animals. Analysis of variance, Mann-Whitney,
Kruskal-Wallis, Fisher exact, and 2 tests were performed
(Statistix, Tallahassee, Fla; SAS Institute Inc, Cary, NC).
Data are presented as mean  standard deviation, and P 
.05 was considered significant. The dressings were initially
ranked according to survival because survival time of the
animals across the 3-hour experiment directly affected
quantitative blood loss levels; and secondarily, according to
bleeding arrest, which was determined by quantitative as-
sessment of aspirated blood.
RESULTS
The study used 69 of the 88 originally intended animals
(n  8 animals per group). Three pigs died before T10 of
excessive initial bleeding and were excluded from analyses.
The final analysis included 66 animals. Dressings IC, HC,
esusci
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was tested on six because these dressings showed repeated
failure. Overall, 35 of 66 pigs survived to T180, the exper-
imental end point.
There was no difference between groups for the base-
line parameters listed in Table II. These parameters were
representative of physiologic and hematologic values for
Yorkshire swine in our laboratory. All animals showed
comparable hematology and hemostasis baseline measure-
ments: hematocrit, 25.5% 1.0%; hemoglobin, 8.6% 0.3
g/dL; platelet count, 326  55  106/mL; prothrombin
time, 14.0  0.3 seconds; fibrinogen, 138  21 mg/dL;
reaction time (TEG-R), 593  138 seconds; kinetics
(TEG-K), 171  56 seconds; maximum amplitude (TEG-
MA), 75.7  2.2 mm; pH, 7.42  0.03; lactate, 0.95 
0.11mM; and glucose, 3.4  0.6mM. Hemodynamic pa-
rameters after injury but before treatment (T45 seconds)
were also comparable between groups (Table II). Owing to
blood loss of 18.8%  5.2% EBV, MAP was reduced from
an average baseline of 64.0  11.4 to 32.3  7.9 mm Hg
across groups. The rate of initial rate bleeding (462  128
mL/min) was also comparable in all groups.
Survival. When ranked by the survival rate to the
T180 end point, all dressings were superior to SD (Fig 1).
We used ACS as a benchmark for comparison because it
was deployed for combat when these experiments were
conducted. Compared with 13% for animals treated with
SD, survival rates of animals treated withWS, CEL, XS, and
ACSwere 78% 12%, which was significant (Fisher exact
test, P  .001), and they also significantly outperformed
FP-21, HC, CHI, and BLS, which exhibited the lowest
survival rates (25%  0%, P  .01). AB and IC dressings
had an intermediate rate of survival (50%) and were not
statistically different than the dressings showing the survival
Table II. Baseline and treatment variables according to tr
Variablesa WS CEL
No. 8 8
Pretreatmentc
Weight, kg 29.7  2.6 30.7 
MAP, mm Hg 29.9  6.3 29.5 
Blood loss, % EBV 19.0  6.8 19.8 
Rate of loss, mL/min 490  150 437 
Post-treatmentd
Wound temperature 38.5  0.7 39.1 
Lowest MAP, mm Hg 22.5  1.7 20.9 
Blood loss (% EBV) 5.2  1.6 4.3 
Postresuscitation
Highest MAP, mm Hg 63.8  3.1 60.4 
Blood loss, % EBV 2.8  2.7 2.8 
EBV, Estimated blood volume; MAP, mean arterial pressure; SD, standard
aData are presented as mean  standard deviation.
bSee Table I for descriptions of products that were tested. Preinjury baseline
temperature, 38.2  0.3°C.
cPretreatment, Time 45 seconds except for wound temperature measured a
dPost-treatment Time 15 minutes, time after treatment and before fluid rrate equivalent to ACS or better. There was a gradation insurvival time that paralleled the survival rates. The time of
survival for treatment with the four top dressings averaged
160  13 minutes, whereas the bottom four dressings
Fig 1. A, Rate of survival (%) across all dressings. B, Time of
survival (minutes). There were eight animals in each group, except
for AB (n  6) and CHI, FP-21, HC, BLS (n  4).
ent with hemostatic product
Groupsb
XS ACS IC
8 8 4
30.5  3.5 31.0  2.7 27.5  3.2
32.0  8.2 32.8  9.9 35.8  12.1
17.0  5.5 18.0  5.3 18.8  6.9
462  106 421  167 445  96
38.5  0.7 42.0  1.0 38.1  1.0
22.9  3.1 24.4  2.0 20.0  5.7
6.5  3.4 5.0  2.2 14.2  5.1
57.8  6.4 51.6  6.9 62.8  14.3
9.4  3.6 13.3  5.5 4.1  2.0
g.
0) data (not included in the table) were: MAP, 64.0 11.4 mmHg; wound
eak (T4 min).
tation, additional post-treatment blood loss after release of compression.eatm
2.6
7.6
5.1
131
2.2
3.9
2.7
5.8
1.9
dressin
(time
t its paveraged 114  75 minutes (2 test, P  .01).
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pressure observed within each group reached levels 30
mm Hg after injury and dressing application. MAP 40
mmHg after application of WS, CEL, XS, ACS, HC, IC,
AB, andCHI; whereas, FP-21, BLS, and SDwere unable to
restore and maintain blood pressures40 mmHg (Fig 2).
Incidence of rebleeding (attainment of hemostasis).
After dressing application (post-treatment) and compres-
sion release, but before fluid resuscitation, blood loss varied
among groups. At least some bleeding was observed after
application with each of the dressings. This bleeding was
typically observed at compression release and upon MAP
increase (Fig 3 and Table III). However, group differences
were documented between dressings in the control of
Fig 2. Restoration of blood pressure: data indicate the highest
mean arterial pressure achieved after fluid resuscitation across all
groups during the 3-hour experiment time (mean  standard
deviation).
Table II. Continued.
G
AB CHI FP-21
6 4 4
28.6  4.2 28.8  2.0 29.9  2.9
38.2  9.1 31.8  5.1 27.8  7.5
16.1  3.6 21.6  1.5 20.6  2.1
359  39 562  78 465  117
37.8  0.6 39.0  1.2 38.3  0.4
1.2  2.7 21.5  5.4 15.5  1.6
14.1  1.7 16.1  6.1 22.7  1.5
47.5  7.0 51.3  14.0 27.0  5.8
15.3  5.7 14.1  8.3 26.5  11.5bleeding. Bleeding (ie, incidence of aspirated blood) uponthe release of manual compression ranged 50% to 62.5% for
XS, WS, CEL, and ACS, and 75% to 100% for all other
dressings. This post-treatment bleeding, with a median
14.1% EBV (range, 5%-43% EBV), decreased MAP in all
groups even further than occurred after injury (Table III).
Upon compensation, while MAP was restored, the same
top four dressings exhibited less incidence of rebleeding.
These four dressings, as well as CHI, resulted in no more
than a 50% incidence of a second bleeding upon restoration
of MAP. The other dressings were less effective, with an
incidence of rebleeding upon MAP increase of 66.7% to
100% and the additional blood loss was 3% to 32% EBV.
Overall, WS and CEL exhibited the lowest incidence of
rebleeding.
Post-treatment blood loss. Blood loss was divided
Fig 3. Incidence of rebleeding for each group is shown after
release of compression (black box) and upon restoration of mean
arterial pressure after fluid resuscitation (white box).
b
HC BLS SD
4 4 8
28.7  0.7 30.0  2.9 29.8  2.6
30.2  4.4 37.2  3.5 35.6  8.6
16.2  2.8 15.7  6.3 21.1  5.7
401  87 473  114 539  151
38.3  0.5 38.2  0.3 38.2  0.7
21.0  3.8 8.7  3.7 20.9  4.9
17.5  8.0 43.3  13.8 12.5  3.8
44.8  4.7 35.8  10.7 34.8  7.2
29.1  4.3 32.1  19.5 16.9  6.8roupsbetween blood absorbed in both the test and SDs and the
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blood loss, as quantified by both absorbed and aspirated
amounts, is a direct indication of the capacity of the dress-
ing to arrest hemorrhage. Dressings promoting higher
survival rates showed better bleeding control with less
blood aspirated or absorbed into the dressings. With rank-
ing based solely on aspirated blood, the top dressings were
WS, CEL, IC, ACS, and XS. This order shows consis-
tency with survival ranking, with the exception of IC. In
parallel with analysis of the survival rate between the top
four dressings and the bottom four dressings, analysis on
aspirated blood yielded the same result (Mann-Whitney
test, P .001). Blood retained in the hemostatic dressings
is illustrated in the black boxes in Fig 4. This suggests that
Table III. Occurrence of rebleeding determined at time
of release of compression and upon increase of mean
arterial pressure as described in Materials and Methods
Groupa
Occurrence of rebleeding
Death after
first bleed (%)None (%) Once (%) Twice (%)
WS 37.5 50 12.5 0
CEL 50 25 25 0
XS 12.5 75 12.5 0
ACS 25 37.5 37.5 0
IC 25 25 50 25
AB 0 33.3 66.7 0
CHI 25 25 50 0
FP-21 0 25 75 25
HC 0 25 75 0
BLS 0 50 50 25
SD 12.5 37.5 50 12.5
SD, Standard dressing.
aSee Table I for descriptions of products that were tested.
Fig 4. Post-treatment blood loss. Blood loss was divided in three
categories Clear boxes indicate aspirated blood loss, hatched boxes
indicate blood in standard dressing and black boxes indicate blood
in hemostatic dressings. Error bars indicate standard deviation.
EBV, Estimated blood volume.WS, CEL, IC, and SD dressings had the highest absorbingcapacity, whereas CHI, HC, and BLS had the lowest ab-
sorbing capacity.
Additional characteristics of test hemostatic dres-
sings. Additional observations made during the experi-
ments regarding each dressing are illustrated in Appendix
(online only). In addition to survival and hemostasis, the
dressings were also evaluated for their ease of application
and removal. This was subjectively assessed on a scale: easy,
intermediate, or difficult. The difficulty in removing loose
granular products was demonstrated by the high number of
individual particles left behind, whereas the ease of remov-
ing fabric and solid dressings provided a clean wound ready
for repair.
DISCUSSION
We tested 10 new hemostatic dressings in a 4-mm
femoral arterial puncture swine model. This model was
initially developed at the Institute of Surgical Research
(ISR), San Antonio, Texas, using a 6-mm punch injury as
described by Kheirabadi et al.11,20,22 These two models, 4-
and 6-mm puncture, showed similar levels of severity,
causing 100% or 87% death, respectively, in swine treated
with standard of care (ie, compressed gauze), with an initial
rate of free bleeding blood loss of 462 mL/min in the
4-mm puncture vs 850 mL/min in the 6-mm puncture.
With the ISR model, the animal was splenectomized and
fluid resuscitation occurred at 30 seconds after the dressing
was applied. Additional crystalloid was also provided to
re-establish normotension. In our model, restoration of
blood pressure is the effect of the dressing and natural
physiologic compensation after one 500-mL bolus infusion
at 15 minutes without additional fluid.
In our model, MAP decreased immediately after the
arterial puncture injury during active bleeding (on average
a 19% EBV blood loss caused MAP to drop to 32 mmHg).
MAP decreased further in dressings that did not prevent
rebleeding at release of compression and was observed in
approximately 50% of the experiments for each of the
dressings. This blood loss, in addition to blood lost after
resuscitation, brought the total post-treatment blood loss
to30% EBV forWS, CEL, XP, and IC, and to50% EBV
for AB, HC, FP-21, and BLS.
Survival rate was not significantly different among in-
dividual treatment groups, but survival rates and times for
the top performing dressings as a group (WS, XS, CEL and
ACS) were significantly higher compared with the group
of less effective dressings in this model (CHI, FP-21, HC,
BLS). This relationship was consistent for post-treatment
blood loss and incidence of rebleeding. Most of the dress-
ings exhibited rebleeding during the release of compression
or an increase in MAP, or both. Overall, WS, XS, CEL, and
ACS—the best performing dressings in this model as
determined by survival—had lower incidences of blood loss
at both of these times.
All other dressings, which were better than the SD,
were less effective in terms of bleeding control, particularly
during the secondary incidence of rebleeding. Most of the
SD-treated animals died within about 60 minutes due to
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indicates that in high shear-rate bleeding, absorption alone
is not sufficient to inhibit rebleeding and promote survival.
However, fabric-like dressings that are absorbent and also
have additional hemostatic properties (ie, XS) provided
better bleeding control by promoting early blood clotting
and stopping blood from oozing into the dressings, hence
increasing survival.
The incidence of rebleeding after compression is re-
leased (first possible incidence) was high in the less effective
dressings and was often fatal. It is compelling that the top
performing dressings that controlled bleeding in this model
corresponded to the same dressings previously observed as
superior in the transection model.19 These dressings, de-
spite being consistently effective in comparison of multiple
dressings, did yield more blood loss and less survival in the
puncture model than in the transection model. This obser-
vation substantiates the severity of the hemorrhagic injury
in this model despite there being no soft tissue injury, as is
the case in the transection model.
Treatment with IC and AB dressings resulted in inter-
mediate levels of survival (50%). Additional animals were
allowed in the AB group because the initial performance
was positive (3 of 4 survived). However, massive bleeding
occurred with both of these dressings due to insufficient
clotting. As blood filled the wound cavity, AB seemed
unable to promote rapid clotting. Also, the IC membrane
did not seem to allow ready absorption, which resulted in
significant blood loss around the dressing edges in failed
cases. Of the four other dressings, which yielded 25%
survival, CHI, FP-21, and HC exhibited little initial ab-
sorption, followed by a high incidence of rebleeding. BLS,
owing to the small size of the dressing unit, was unable to
contain massive bleeding.
These findings suggest that with high shear bleeding,
success is significantly influenced by the capacity of the
dressing to both rapidly absorb blood and promote clot-
ting. In terms of blood loss, survival is a confounding
factor; animals that survived for a longer time had more
occasions to experience rebleeding with increased MAP.
The lack of rebleeding was an indication of dressing effi-
cacy. On the other hand, animals that bled excessively after
15 minutes tended to die more rapidly, thereby exhibiting
a lower total blood loss.
The 5-minute compression stage is necessary to pro-
mote close contact between the dressing and the source of
bleeding. This compression procedure seems key for effi-
cacy, initiating contact and adherence soon after applica-
tion; otherwise, risk of rebleeding may be high, especially
for dressings that depend on adherence (eg, HC and FP-
21). It is obvious that in this puncture injury model, where
the vessel is not fully sectioned and always under risk of high
shear-rate bleeding, full obstruction of the created orifice
by natural clot formation is almost unattainable. Thus, the
initial closing of the aperture relies almost solely on the firm
contact between dressing and blood vessel. This might
explain why, when there is not a firm contact, rebleeding
occurred at the release of compression. Granular or powderdressings are able to create a more complete seal and
control bleeding better when MAP increases because they
closely surrounded the vessel. In the firm-dressing cate-
gory, flexible fabric-like dressings may offer a better first
contact with the vessels (XS performed better than FP-21).
In some cases, it seemed that a firm seal, when established
for any dressing, created a pool of blood trapped in the
wound underneath the dressing, which might eventually
clot and act as a vascular plug.
Dressings that did not perform well in this model were
still found to have interesting properties. At least one
animal survived in each of the groups, suggesting that each
of these test dressings may work in particular conditions.
The dressings were tested as instructed by the manufac-
turer, but other factors could have contributed to their
relatively less effective performance; their unit size could
have been too small (BLS, FP-21), or the shape did not
conform the wound (ie, IC, FP-21). The shape and rigidity
of IC, for instance, was either extremely beneficial or ex-
tremely detrimental to its performance. The coveringmem-
brane did not easily dissolve and prevented rapid contact
and absorption of blood with the hemostatic powder. In
the few cases when the membrane did dissolve or break, the
powder was effective in absorbing blood.
Dressings with strong adhesive properties (HC, CHI)
were able to control bleeding extremely well when a strong
seal was formed around the wound. A broken seal, how-
ever, became the source of leakage, leading to increased
blood loss. We also observed that some granular materials
were only partially soaked due to groin anatomy, placement
of the dressing, or direction of bleeding. This posed prob-
lems during the removal stage, particularly for the powders
(IC, CEL and WS). Removal by scooping the unabsorbed
powder left a tremendous amount of residue in the wound
that could be removed only with a high volume of rinse
solution.
A major difference between the puncture injury model
used in this study and the transection injury model used in
previous protocols is that immediately after injury, the
initial blood loss is lower and MAP remains high. This
increases the chance to disrupt hemostasis in the puncture
model and subsequently causes more blood loss and tends
to lead to early death. Survival rate in the transection model
was higher, despite an initially higher blood loss, likely
because the animals were hypotensive at the time the he-
mostatic dress was applied. They also benefited from vessel
retraction that occurred with this injury. Overall, the arte-
rial puncture model is different yet relevant and very appro-
priate for bandage testing of severe hemorrhage observed
in combat casualties.
CONCLUSIONS
WS, CEL, and XP performed similarly to ACS in
controlling bleeding. The dressings have a comparably low
incidence of rebleeding, and if rebleeding occurs, they limit
blood loss and allow restoration of MAP 50 mm Hg,
which ultimately leads to survival. Alternately, CHI, FP-21,
HC, and BLS did not perform as well in this model of a
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 3 Arnaud et al 639puncture injury with high-pressure bleeding. These dress-
ings exhibited a high incidence of rebleeding, leading to a
high volume of blood loss and a MAP40 mmHg, which
did not support survival for the 3-hour experimental pe-
riod.
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Hemostatic dressings
by type Advantages
Powder/granular agents
ACS Easily applied, conforms to the wound
easily removed
Celox Easily poured in the wound, conforms
to all cavities in the wound; forms a
uniform gel that can mix with
clotted blood
Instaclot Very effective powder; firm clot and
packing when soaked
WoundStat Easily poured in the wound, conforms
to all cavities in the wound; forms
clay when soaked; promotes firm
clot; could be remixed in the wound
in case of rebleeding
Solid (rigid) agents
Chitoflex Roll fits well in wound; readily
dissolves in blood, easily removed
HemCon May seal wound very well; good abilit
to retain clot at tissue interface whe
adherent; easily removed if non
adherent; lightweight
Polymem FP-21 Good gel; dissolves in blood; very ligh
Solid (flexible) agents
Alpha Bandage Easy fit to wound; easily
removed–lightweight
BloodStop Easy fit to wound; may form good clo
with low blood flow; easily removed
very light
X-Sponge Easily applied; fits wound; good clot
formation; light weightessings used in the puncture injury model
Disadvantages
Ease of
removal
Fitness of the
dressing to
the wound
, Hemorrhage arrest depends on the
amount of blood present in the
wound; clotting weak
Easy Adequate
Powder need to be soaked for easy
removal; blood distribution is
not homogeneous; quite messy
to remove if not completely
soaked
Messy if not
soaked
Adequate
Fragile packaging membrane
breaks easily before application;
packaging membrane hinders
contact with blood; messy to
remove
Messy if not
soaked
Not pliable
Quite messy to remove if not
completely soaked; heavier than
other products
Messy if not
soaked
Adequate
May not adhere enough to stop
blood immediately
Easy Adequate
y
n
Does not always seal the wound;
allows leak through unattached
material; blood does not stick on
the upper surface; difficult to
remove when adherent
Easy Not pliable
t Awkward fitting to wound; needs
additional material
Intermediate Not pliable
Weak absorption; weak clot
formation
Easy Adequate
t
;
Product not effective for severe
bleeding; insufficient sample size
Easy Adequate
Needs initial pressure to make it Easy Adequate
